SGLT2 inhibitors reduce recurrent flares and hospitalization

1. In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those using dipeptidyl peptidase 4 inhibitors (DPP-4is). 2. Those who used SGLT2 inhibitors also presented to the emergency department (ED) less frequently for gout-related visits than those using DPP-4is. Evidence Rating Level: 1 (Excellent) Study

Related Keywords

Canada , United Kingdom , British , , International Statistical Classification Of Diseases , Health Problems , Minute Medicine Inc , Rating Level , Gout With Sodium , Patients With Type , British Columbia , International Statistical Classification , Related Health Problems , Confidence Interval , Chronic Disease , Dipeptidyl Peptidase 4 Inhibitors , Endocrinology , Gout , Inflammatory Arthritis , Sglt 2 Inhibitors , Sodium Glucose Cotransporter 2 Inhibitors ,